Recently, it was reported that PD-1/PD-L1 immunotherapy increased the risk of atherosclerosis-related cardiovascular disease among patients with cancer and that the immune response of the PD-1/PD-L1 pathway in cardiovascular disease is related to the severity of atherosclerosis (25). This evidence concerns the gene CD274 and atherosclerosis.